Novakand Pharma AB (publ) (LARK) — Cash Flow-to-Debt Ratio
Novakand Pharma AB (publ) (LARK) has a Cash Flow-to-Debt Ratio of -1.32x as of December 2025, meaning its operating cash flow of Skr-1.64 Million could theoretically repay -1% of its total liabilities (Skr1.24 Million) in one year. For the full cash flow conversion analysis, see Novakand Pharma AB (publ) (LARK) cash flow conversion.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Novakand Pharma AB (publ) Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Novakand Pharma AB (publ) across 14 annual periods. See LARK free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Annual Cash Flow-to-Debt Ratio for Novakand Pharma AB (publ) (2012–2025)
Year-by-year debt coverage analysis for Novakand Pharma AB (publ). Check Novakand Pharma AB (publ) cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -10.31x | Skr-12.78 Million | Skr1.24 Million | ▼ -48.1% |
| 2024 | -6.96x | Skr-29.95 Million | Skr4.30 Million | ▲ +5.3% |
| 2023 | -7.35x | Skr-30.56 Million | Skr4.16 Million | ▼ -169.1% |
| 2022 | -2.73x | Skr-16.67 Million | Skr6.10 Million | ▼ -198.1% |
| 2021 | 2.78x | Skr22.11 Million | Skr7.94 Million | ▲ +158.0% |
| 2020 | -4.80x | Skr-38.35 Million | Skr7.98 Million | ▼ -422.9% |
| 2019 | -0.92x | Skr-21.60 Million | Skr23.51 Million | ▼ -6018.6% |
| 2018 | 0.02x | Skr227.60K | Skr14.66 Million | ▲ +100.3% |
| 2017 | -5.86x | Skr-9.53 Million | Skr1.63 Million | ▲ +46.2% |
| 2016 | -10.88x | Skr-8.81 Million | Skr809.66K | ▼ -19.7% |
| 2015 | -9.09x | Skr-6.29 Million | Skr691.73K | ▼ -752.1% |
| 2014 | -1.07x | Skr-620.67K | Skr582.04K | ▲ +83.9% |
| 2013 | -6.64x | Skr-272.15K | Skr40.98K | ▼ -3426.4% |
| 2012 | 0.20x | Skr59.21K | Skr296.58K | — |